Zobrazeno 1 - 10
of 297
pro vyhledávání: '"Hideki Hirakata"'
Autor:
Masahiro Eriguchi, Kazuhiko Tsuruya, Marcelo Lopes, Brian Bieber, Keith McCullough, Roberto Pecoits‐Filho, Bruce Robinson, Ronald Pisoni, Eiichiro Kanda, Kunitoshi Iseki, Hideki Hirakata
Publikováno v:
ESC Heart Failure, Vol 9, Iss 2, Pp 1138-1151 (2022)
Abstract Aims Cardiac troponin (cTn) and B‐type natriuretic peptide (BNP) are elevated in haemodialysis (HD) patients, and this elevation is associated with HD‐induced myocardial stunning/myocardial strain. However, studies using data from the in
Externí odkaz:
https://doaj.org/article/c1b81393c8354925890a7801464690df
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract The ASTRIO study was a randomised, multicentre, 24-week study that compared the effects of ferric citrate hydrate (FC) and non-iron-based phosphate binders (control) on anaemia management in haemodialysis (HD) patients receiving erythropoies
Externí odkaz:
https://doaj.org/article/7705fdeb260f4bdd8e47266b578929ca
Publikováno v:
BMC Nephrology, Vol 22, Iss 1, Pp 1-12 (2021)
Abstract Background Fibroblast growth factor-23 (FGF23) and α-klotho are associated with anemia in patients with chronic kidney disease. In this post hoc analysis of the ASTRIO study (UMIN000019176), we investigated the relationship between FGF23 an
Externí odkaz:
https://doaj.org/article/75f8f795c9ba4dac989e29a7b7c58b1c
Autor:
Tadao Akizawa, Masaomi Nangaku, Takuhiro Yamaguchi, Ryosuke Koretomo, Kazuo Maeda, Yuya Miyazawa, Hideki Hirakata
Publikováno v:
Kidney Diseases, Pp 1-9 (2021)
Introduction: Enarodustat (JTZ-951) is a new oral hypoxia-inducible factor-prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease (CKD). We conducted a phase 3 study to compare the efficacy and safety of enarodustat with d
Externí odkaz:
https://doaj.org/article/756ce7cdeb974b31b371c3e53f66b5da
Autor:
Eiichiro Kanda, Marcelo Barreto Lopes, Kazuhiko Tsuruya, Hideki Hirakata, Kunitoshi Iseki, Angelo Karaboyas, Brian Bieber, Stefan H. Jacobson, Indranil Dasgupta, Bruce M. Robinson
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract The identification of malnutrition-inflammation-complex (MIC) and functional status (FS) is key to improving patient experience on hemodialysis (HD). We investigate the association of MIC and FS combinations with mortality in HD patients. We
Externí odkaz:
https://doaj.org/article/a6ce3f5ccf3c4c69bd95cf49e823d086
Autor:
Shunsuke Yamada, Hokuto Arase, Hisako Yoshida, Hiromasa Kitamura, Masanori Tokumoto, Masatomo Taniguchi, Hideki Hirakata, Kazuhiko Tsuruya, Toshiaki Nakano, Takanari Kitazono
Publikováno v:
Kidney Medicine, Vol 4, Iss 3, Pp 100408- (2022)
Rationale & Objective: Malnutrition-inflammation complex syndrome (MICS) is common in patients receiving hemodialysis and increases the risks of morbidity and mortality. However, few studies have examined the overall impact of MICS on disorders of th
Externí odkaz:
https://doaj.org/article/30d8512e19b444a4a34c7f38830699fc
Autor:
Shunsuke Yamada, Toshiaki Nakano, Shoji Tsuneyoshi, Hokuto Arase, Sho Shimamoto, Masatomo Taniguchi, Masanori Tokumoto, Hideki Hirakata, Hiroaki Ooboshi, Kazuhiko Tsuruya, Takanari Kitazono
Publikováno v:
Renal Replacement Therapy, Vol 6, Iss 1, Pp 1-9 (2020)
Abstract Background Protein-energy wasting (PEW) is a frequently observed complication that leads to increased mortality in hemodialysis patients. However, a multifaceted assessment of PEW by combined objective nutritional parameters has not yet been
Externí odkaz:
https://doaj.org/article/01c55ccca56040fc8d5b4169c76efbf6
Autor:
Yusuke Kuroki, Koji Mitsuiki, Kaneyasu Nakagawa, Kazuhiko Tsuruya, Ritsuko Katafuchi, Hideki Hirakata, Toshiaki Nakano
Publikováno v:
BMC Nephrology, Vol 21, Iss 1, Pp 1-6 (2020)
Abstract Background Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disease that leads to end-stage kidney disease if only a poor response to plasma exchanges (PEs) or eculizumab therapy is achieved. Case presentation A 58-year-old Ja
Externí odkaz:
https://doaj.org/article/c6ac9f39541742fb84d75f43761d98b6
Autor:
Ichiei Narita, Terumasa Hayashi, Shoichi Maruyama, Takao Masaki, Masaomi Nangaku, Tomoya Nishino, Hiroshi Sato, Tadashi Sofue, Takashi Wada, Enyu Imai, Manabu Iwasaki, Kyoichi Mizuno, Hiroki Hase, Masahiro Kamouchi, Hiroyasu Yamamoto, Tatsuo Kagimura, Kenichiro Tanabe, Hideki Kato, Takehiko Wada, Tomoko Usui, Tadao Akizawa, Hideki Hirakata, Yoshiharu Tsubakihara
Publikováno v:
PLoS ONE, Vol 17, Iss 11, p e0277921 (2022)
Among non-dialysis-dependent chronic kidney disease (ND-CKD) patients, a low hematopoietic response to erythropoiesis-stimulating agents (ESAs) is a predictor for poor renal and cardiovascular outcome. To assess the method for evaluating hyporesponsi
Externí odkaz:
https://doaj.org/article/2e61b3508b6348a18fef1530569eede2
Autor:
Teppei Sakoh, Masatomo Taniguchi, Shunsuke Yamada, Shotaro Ohnaka, Hokuto Arase, Masanori Tokumoto, Taihei Yanagida, Koji Mitsuiki, Hideki Hirakata, Toshiaki Nakano, Takanari Kitazono, Kazuhiko Tsuruya
Publikováno v:
Kidney Medicine, Vol 1, Iss 5, Pp 296-306 (2019)
Rationale & Objective: The short- and long-term impact of conversion of dialysate calcium concentration from either 2.5 or 3.0 mEq/L to 2.75 mEq/L on mineral and bone metabolism remains unknown in hemodialysis patients. Study Design: Nonrandomized in
Externí odkaz:
https://doaj.org/article/44c66d919f614e3e8f5c119d26ba3fde